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ABSTRACT
Objectives To study clinical predictors for radiographic
progression after 1 year in an early rheumatoid arthritis
(RA) trial.
Methods In the SWEFOT trial population, disease
modifying antirheumatic drug (DMARD) naïve RA
patients started methotrexate; 3-month responders
(DAS28 <3.2) continued (n=147), while non-responders
were randomised to addition of sulfasalazine
+hydroxychloroquine (n=130) or inﬂiximab (n=128).
X-rays were scored by the Sharp-van der Hejde score
(SHS) method and radiographic progression was deﬁned
as a ≥5 increase after 1 year. Potential baseline
predictors of radiographic progression were tested using
multivariable logistic regression, adjusted for potential
confounders.
Results 79 of 311 patients with available radiographs
at baseline and follow-up had radiographic progression.
The following baseline parameters were independent
predictors of radiographic progression at 1 year: baseline
erosions (adjusted OR=2.29, 95% CI 1.24 to 4.24),
erythrocyte sedimentation rate (adjusted OR per tertile
increase=1.72, 95% CI 1.12 to 2.65) and C-reactive
protein (adjusted OR per tertile increase=1.52, 95% CI
1.03 to 2.26). Current smoking was an independent
predictor of radiographic progression (adjusted OR=2.17,
95% CI 1.06 to 4.45). These results remained after
further adjustment for treatment strategy. Three-
dimensional matrix including current smoking status,
erosions and C-reactive protein tertiles showed a
12–63% risk gradient from patients carrying none
compared with all predictors. Rheumatoid factor (RF)/
anti-cyclic citrullinated peptide (anti-CCP) positivity did
not signiﬁcantly predict radiographic progression using
SHS increase ≥5 as cut-off. In a secondary exploratory
analysis using cut-off >1, both RF and anti-CCP
positivity were signiﬁcant predictors in the unadjusted,
but not the adjusted analyses. The other parameters also
remained signiﬁcant using this lower cut-off.
Conclusions In addition to previously described
predictors, we identiﬁed smoking as a strong
independent risk factor for radiographic progression in
early RA.
Trial registration number NCT00764725.
INTRODUCTION
In rheumatoid arthritis (RA), broad evidence sup-
ports that treatment strategies focusing on early
inﬂammatory control decrease radiographic progres-
sion.1 Nevertheless, a proportion of patients pro-
gress, some despite having low disease activity.2 Since
accumulation of joint damage over time correlates
with decline in both functional capacity and quality
of life, it is important to identify those patients at
diagnosis who are likely to develop signiﬁcant radio-
graphic progression.3 4 Indeed, several studies have
recently attempted to construct clinically useful risk
matrices to predict so-called ‘rapid radiographic pro-
gression’ (RRP), corresponding to an increase in
Sharp-van der Hejde score (SHS) of ≥5 after 1 year,
based on both early RA trials5 6 and cross-sectional
cohorts7; their performance has been tested in both
early8 and unselected9 RA populations. Among the
baseline clinical parameters that have been identiﬁed
as predictors and included in those matrices are
inﬂammatory markers (erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP)), radiographic
erosions at baseline, swollen joint counts and auto-
antibody status.
However, none of these studies has evaluated
whether smoking habits associate with RRP after
1 year, although several studies, especially earlier
ones before the era of biological treatment, had indi-
cated that RA patients who smoke develop more
radiographic damage.10–13 Furthermore, current
smokers have been shown to respond worse clinically
to both methotrexate and tumour necrosis factor α
(TNFα) inhibitors in early RA.14 15
Here, we examined baseline predictors of radio-
graphic progression in the SWEFOT trial popula-
tion,16 17 including previously known ones as well
as smoking habits.
METHODS
Participants in the investigator-initiated, multicentre,
randomised SWEFOT trial (n=487) served as our
study base; it has been described in detail else-
where.16 17 Brieﬂy, inclusion criteria were RA accord-
ing to the 1987 revised American College of
Rheumatology (ACR) criteria, age ≥18 years,
symptom duration <1 year, 28-joint disease activity
score (DAS28) >3.2, no previous disease modifying
antirheumatic drug (DMARD) treatment and stable
prednisolone dose, if present, for ≥4 weeks before
entry and throughout the study of ≤10 mg/day.
Patients who achieved DAS28 <3.2 after 3–4 months
continued on methotrexate (MTX, N=147), while
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the other patients were randomised to add either inﬂiximab
(N=128) or both sulfasalazine and hydroxychloroquine (N=130).
Anti-cyclic citrullinated peptide (anti-CCP) antibodies were
measured with the standard ELISA (Immunoscan-RA Mark2
ELISA test, Euro-Diagnostica, Malmö, Sweden) and rheumatoid
factor (RF) was determined by routine methods. Smoking status
was deﬁned as current, past or never cigarette smokers; patients
were also grouped as current smokers versus non-smokers,
pooling past and never smokers in the latter group.
X-rays of hands and feet were obtained at baseline and after
1 year, and analysed by the modiﬁed SHS method.
Radiographic progression was deﬁned as an increase in total
SHS of ≥5 after 1 year, as previously suggested,6 8 which corre-
sponds to the minimal clinically important progression,18 and
has also been referred to as RRP. In a secondary exploratory
analyses, we tested a lower cut-off of SHS >1 after 1 year.
For this study, 311 patients from the SWEFOT trial were
included, based mostly on availability of full sets of radiographs
at baseline and 1-year follow-up. Their baseline characteristics
(table 1) were representative for the whole study population,
and did not differ from the subgroup included in the multivari-
able analyses which had complete data including smoking
status.
Statistical methods
The primary outcome measure was radiographic progression
(increase in total SHS of ≥5 after 1 year), and the association
between each baseline variable and the risk of radiographic pro-
gression after 1 year (yes/no) was calculated using logistic regres-
sion. The results were expressed as ORs with 95% CIs. First,
unadjusted analyses were performed for baseline variables,
chosen and categorised based on previous reports5 6 8 and clin-
ical relevance (see table 2). For the unadjusted analyses, correla-
tions between baseline variables were assessed by Spearman
correlation. As expected, high co-linearity was observed for
health assessment questionnaire (HAQ) score and DAS28 and
its components, so only HAQ was kept in the model, and
excluded when DAS28 and its components, respectively, were
analysed. Finally, we further adjusted for treatment strategy by
adding a three group variable to the model indicating whether
the patient continued MTX or which arm he/she was rando-
mised to.
Using the parameters showing the strongest association with
radiographic progression, three-parameter risk matrices were
created, showing the actual proportion of patients with radio-
graphic progression in each box and the total number of
patients in that box.
Statistical analysis was performed using SAS V.9.1. All tests
were two-sided and the signiﬁcance level was set at 0.05.
This study was approved by the regional ethical committees of
the participating clinics and registered at http://www.clinicaltrials.
gov (NCT00764725). All patients were provided with oral and
written information prior to inclusion, and consented to partici-
pate by signing the informed consent document.
RESULTS
The baseline characteristics for the 311 patients with radio-
graphic data at baseline and 1 year follow-up are shown in
table 1; 79 had radiographic progression.
The association between each baseline parameter and radio-
graphic progression was tested using unadjusted logistic regres-
sion (table 2). Signiﬁcant associations were observed for current
smoking, baseline erosions, DAS28 and its inﬂammatory compo-
nents (CRP, ESR), while no signiﬁcant associations were
observed for the previously reported predictors swollen joint
count and auto-antibody status (RF, anti-CCP antibodies). These
signiﬁcant associations remained when tested in a multivariable
model (table 2). Of the 269 patients in the multivariable model,
80 remained on methotrexate monotherapy, while the others
were randomised to add inﬂiximab (n=94) or to triple therapy
(n=95). Further adjustment for treatment strategy did not
modify the observed associations between the signiﬁcant predic-
tors and radiographic progression: current smokers versus
non-smokers (OR=2.78, 95% CI 1.48 to 5.19), erosions
(OR=2.21, 95% CI 1.24 to 3.97), CRP (<10, 10–35,
>35 mg/L, OR=1.49, 95% CI 0.98 to 2.25) and ESR (<21,
21–50, >50 mm/h, OR=1.62, 95% CI 1.03 to 2.53). Since
auto-antibody status was, in contrast to some previous publica-
tions, not found to be a signiﬁcant predictor of radiographic
progression using the cut-off of SHS score increase ≥5, we
made a secondary exploratory analysis to see whether it was a
predictor using a lower cut-off threshold (SHS score increase
>1). As shown in table 3, both positivity for RF (OR=1.75,
95% CI 1.07 to 2.86) and anti-CCP (OR=1.64, 95% CI 1.02
to 2.64) or both (OR=1.50, 95% CI 1.12 to 2.02) were then
signiﬁcant predictors in the unadjusted analyses, although only a
trend in the multivariable model. The other parameters also
Table 1 Baseline characteristics of SWEFOT patients with
radiographic data
All*
(n=311)
In model†
(n=269)
Male, n (%) 87 ((28%) 75 (28%)
Age, years, median (IQR) 57 (46–64) 57 (46–63)
Cigarette smoking status
Current smokers, n (%) 65 (24%) 64 (24%)
Past smokers, n (%) 104 (37%) 100 (37%)
Never smokers, n (%) 106 (39%) 105 (39%)
Symptom duration, months, median (IQR) 5 (4–8) 6 (4–9)
RF positive, n (%) 208 (67%) 179 (67%)
Anti-CCP antibody positive, n (%) 180 (61%) 156 (62%)
RF and anti-CCP positive, n (%) 146 (50%) 125 (49%)
Sharp van der Hejde score, median (IQR) 2 (0–6) 2 (0–6)
Joint space narrowing score, median (IQR) 0 (0–3) 0 (0–3)
Erosion score, median (IQR) 0 (0–2) 0 (0–2)
Erosions, n (%) 128 (41%) 114 (42%)
Concurrent prednisolone, n (%) 42 (14%) 35 (13%)
Concurrent NSAIDs, n (%) 192 (62%) 171 (64%)
HAQ score, median (IQR) 1.1 (0.8–1.6) 1.1 (0.9–1.6)
DAS28, median (IQR) 5.8 (5.0–6.4) 5.8 (5.0–6.4)
28-Swollen joint count, median (IQR) 10 (6–14) 10 (6–14)
28-Tender joint count, median (IQR) 8 (5–13) 8 (5–13)
C-reactive protein, median (IQR) 19 (9–46) 19 (9–47)
Erythrocyte sedimentation rate, median (IQR) 34 (22–54) 35 (22–54)
VAS–patient global health, median (IQR) 59 (40–74) 59 (41–74)
VAS–pain, median (IQR) 59 (42–73) 60 (44–73)
Shared epitope, n (%) 208 (74%) 177 (73%)
*In the whole group/multivariable model, missing numbers were as follows: RF,
n=2/2; anti-CCP, n=16/14; smoking status, n=36/0; shared epitope, n=28/25; HAQ
score, n=7/0; VAS scales, n=3/0; symptom duration, n=1/0.
†Multivariable model shown in table 2. There were no significant differences
compared to the whole group.
Anti-CCP, anti-cyclic citrullinated peptide; DAS28, 28-joint disease activity score; HAQ,
Health Assessment Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; RF,
rheumatoid factor; VAS, visual analog scale.
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remained signiﬁcant using this lower cut-off (current smoking
habits, baseline erosions, DAS28, CRP and ESR).
Based on this, a three-dimensional matrix was constructed
including current smoking status, baseline erosions and CRP
(ﬁgure 1). A step-up gradient was observed, where 63% of the
patients carrying all the predictors had developed radiographic
progression after 1 year, in comparison to only 12% of patients
without these three baseline predictors. A similar gradient was
observed within each of the treatment subgroups (ﬁgure 2), and
in men and women (ﬁgure 3).
A risk matrix reported by Visser et al5 from another early RA
trial population, also including erosions (divided by number)
and CRP levels as well as auto-antibody status, was also tested
(see ﬁgure 1). Furthermore, we made separate analyses for
anti-CCP positive and anti-CCP negative patients, showing the
lowest proportion with radiographic progression in anti-CCP
negative patients lacking all baseline predictors.
DISCUSSION
In this standard care-based trial on early DMARD naïve RA
patients, we conﬁrmed that baseline radiographic erosions and
levels of inﬂammatory markers predict the risk of radiographic
progression after 1 year. Furthermore, current smoking habits
turned out to be a strong independent predictor of radiographic
progression, a ﬁnding perhaps not so surprising, since several
older studies have previously reported an association between
cigarette smoking and a more severe RA.10–15 Recently de Rooy
et al19 performed a meta-analysis of six RA cohorts using radio-
graphs from different follow-up time-points and found signiﬁ-
cantly more severe joint damage over time in smokers, although
only signiﬁcant in those from BARFOT and Leiden when ana-
lysed separately. However, smoking habits have not been
included in any of the recent studies on risk matrix of
radiographic progression, often referred to as RRP. When we
constructed a risk matrix including the strongest predictors—
smoking status, erosions and CRP tertiles—a step-up gradient
was observed from 12% up to 63% risk of radiographic pro-
gression in patient with no as compared with all risk factors.
Current smokers with baseline erosions had ≥60% risk of radio-
graphic progression, irrespective of grade of inﬂammation.
Furthermore, a previously reported early RA trial-based risk
matrix,5 including autoantibody status instead of smoking
status, performed reasonably well in our trial population. Given
that, and the fact that anti-CCP positive RA is regarded as an
aetiologically distinct and more severe disease subset, we made
separate matrices for anti-CCP positive and negative disease.
Current smokers with erosive disease had a high risk of radio-
graphic progression in both subsets, while the lowest risk was
Table 2 Predictors of rapid radiographic progression (RRP, SHS score increase ≥5) at 1 year follow-up of the SWEFOT trial*
All patients Patients in multivariable model
Unadjusted OR (95% CI) Unadjusted OR (95% CI) Adjusted OR (95% CI)†
Number 311 269 269
Number with RRP 79 72 72
Demographic
Male 1.61 (0.93 to 2.78) 1.86 (1.05 to 3.32) 1.77 (0.96 to 3.24)
Age (per 10 years increase) 1.01 (0.84 to 1.22) 1.01 (0.83 to 1.23) 0.94 (0.76 to 1.16)
Symptom duration (per month←) 1.06 (0.98 to 1.14) 1.03 (0.95 to 1.12) 1.02 (0.93 to 1.11)
Smoking habits
Current vs never smokers 2.33 (1.20 to 4.51) 2.49 (1.28 to 4.85) 2.25 (1.12 to 4.54)
Past vs never smokers 0.73 (0.38 to 1.42) 0.75 (0.38 to 1.47) 0.75 (0.38 to 1.48)
Current smokers vs non- smokers 2.70 (1.50 to 4.87) 2.85 (1.57 to 5.16) 2.67 (1.44 to 4.95)
Baseline disease parameters‡
RF positive 1.44 (0.81 to 2.54) 1.36 (0.75 to 2.46) 1.05 (0.55 to 1.98)
Anti-CCP antibody positive 1.46 (0.84 to 2.53) 1.35 (0.76 to 2.39) 1.00 (0.54 to 1.87)
RF and/or anti-CCP positive§ 1.32 (0.94 to 1.86) 1.27 (0.89 to 1.82) 1.04 (0.71 to 1.54)
Erosions 2.38 (1.41 to 4.00) 2.43 (1.40 to 4.22) 2.28 (1.28 to 4.07)
Concurrent prednisolone use 1.21 (0.58 to 2.49) 1.30 (0.60 to 2.81) 1.21 (0.53 to 2.77)
DAS28 (per unit increase) 1.36 (1.06 to 1.74) 1.30 (1.00 to 1.69) 1.37 (1.04 to 1.81)
Swollen joint count (<10, 10–17, >17) 0.98 (0.63 to 1.51) 1.14 (0.72 to 1.81) 1.32 (0.81 to 2.15)
Tender joint count (per 10 increase) 1.02 (0.66 to 1.56) 0.96 (0.60 to 1.52) 1.08 (0.67 to 1.76)
CRP (<10, 10–35 vs >35 mg/dL) 1.66 (1.18 to 2.34) 1.68 (1.18 to 2.41) 1.52 (1.03 to 2.24)
ESR (<21, 21–50, >50 mm/h) 1.59 (1.09 to 2.30) 1.68 (1.13 to 2.49) 1.67 (1.10 to 2.53)
VAS–global health (per 10 increase) 1.12 (1.00 to 1.26) 1.09 (0.97 to 1.22) 1.09 (0.96 to 1.23)
HAQ (per unit increase) 1.40 (0.93 to 2.08) 1.17 (0.77 to 1.78) 1.12 (0.71 to 1.76)
HLA-DRB1 shared epitope positive 1.57 (0.81 to 3.02) 1.41 (0.72 to 2.77) 1.12 (0.55 to 2.28)
Abbreviations and numbers of missing as in table 1.
*Association between each parameter and the odds of having a rapid RRP after 1 year (yes/no), calculated by logistic regression and expressed as ORs with 95% CIs. ORs for
dichotomised variables are calculated for being positive, and for continuous variables per unit (DAS28, HAQ) or per 10 increase (age, ESR, VAS–global health), while CRP was grouped
as in previous reports (<10, 10–35 vs >53 mg/L), and symptom duration per month increase.
†Adjusted for gender, symptom duration, current smoking, baseline erosions and HAQ.
‡As high co-linearity was observed for anti-CCP and RF status, and also HAQ score and DAS28 and its components, only anti-CCP status and HAQ were kept in the model, and
excluded when RF status or DAS28 and its components, respectively, were analysed.
§Three group comparison, double positive (2), single positive (1), no positive (0).
Anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SHS, Sharp–van
der Heijde.
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observed for non-smokers with low CRP levels. Swollen joint
count has been included in two of the previously reported
matrices,6 7 but no association was observed in our study group.
Consequently, these matrices did not perform well. Replacing
CRP with ESR showed similar results.
The strength of this study is that it is conducted within a clin-
ical trial which was performed in an unselected early RA popu-
lation and reﬂects common standard care, namely that patients
receive methotrexate at diagnosis, and those who did not
achieve a low disease activity after 3–4 months received either
an addition of inﬂiximab, or sulfasalazine together with hydro-
xychloroquine. The ﬁndings for the independent predictors
remained after further adjustment for treatment strategy. Thus,
the matrix may help to identify at baseline those patients at risk
of radiographic progression, irrespective of which treatment is
chosen on clinical grounds. However, the separate risk matrices
for each treatment arm should be interpreted with caution due
to the limited number within smaller subgroups, although these
show an overall similar pattern to that in the whole group.
Further, the non-signiﬁcant associations observed for anti-CCP
status and shared epitope positivity (see crude ORs in table 2)
might have reached signiﬁcance if the statistical power had been
larger. Since anti-CCP or RF positivity has been found to associ-
ate signiﬁcantly in other early RA cohorts, we performed an
exploratory analysis using a lower cut-off threshold of SHS
increase >1: both auto-antibodies were then signiﬁcant predic-
tors in the unadjusted analyses. Nevertheless, current smoking
remained a strong predictor.
The study group was too small to perform a full multivariable
model, so we critically selected the variables to be included as
potential confounders based on previous reports and clinical
relevance. Based on the current knowledge about the pathogen-
esis of RA, smoking induces citrullination and may thus be
regarded as a mediator of anti-CCP positivity. Therefore, we
made stratiﬁed analyses, subgrouping RA into the two aetio-
logically distinct subsets of anti-CCP positive and negative
disease, and evaluating whether an effect modiﬁcation was
present. However, anti-CCP positivity can also be an outcome
of smoking, and thus a potential collider. Given that, and the
fact that anti-CCP positivity did not signiﬁcantly associate with
radiographic progression in our study population (using the
primary deﬁnition of SHS score increase ≥5, although signiﬁ-
cant in an exploratory analysis using >1 as a cut-off ), we did
not include it in the set of adjustment variables and considered
it only as a potential effect modiﬁer, by showing the stratiﬁed
results in the risk matrices, as described above.
One subgroup showed somewhat contra-intuitive ﬁndings.
The proportion of anti-CCP positive non-smokers with low
Table 3 Predictors of radiographic progression at 1 year follow-up of the SWEFOT trial using SHS score increase >1 as cut-off *
All patients Patients in multivariate model
Unadjusted OR (95% CI) Unadjusted OR (95% CI) Adjusted OR (95% CI)†
Number 311 269 269
Number with SvdH score increase >1 136 118 118
Demographic
Male 1.38 (0.84 to 2.26) 1.58 (0.92 to 2.70) 1.44 (0.82 to 2.53)
Age (per 10 years increase) 1.17 (0.99 to 1.38) 1.18 (0.99 to 1.41) 1.12 (0.93 to 1.36)
Symptom duration (per month←) 1.05 (0.98 to 1.13) 1.03 (0.96 to 1.11) 1.01 (0.93 to 1.09)
Smoking habits
Current vs never smokers 2.20 (1.17 to 4.12) 2.34 (1.24 to 4.42) 2.31 (1.18 to 4.54)
Past vs never smokers 0.84 (0.48 to 1.47) 0.88 (0.50 to 1.55) 0.92 (0.52 to 1.65)
Current smokers vs non-smokers 2.39 (1.35 to 4.22) 2.49 (1.40 to 4.42) 2.42 (1.33 to 4.42)
Baseline disease parameters‡
RF positive 1.75 (1.07 to 2.86) 1.83 (1.08 to 3.10) 1.59 (0.90 to 2.79)
Anti-CCP antibody positive 1.64 (1.02 to 2.64) 1.80 (1.07 to 3.01) 1.38 (0.79 to 2.39)
RF and/or anti-CCP positive§ 1.50 (1.12 to 2.02) 1.60 (1.16 to 2.22) 1.38 (0.98 to 1.95)
Erosions 2.39 (1.50 to 3.80) 2.72 (1.65 to 4.49) 2.60 (1.55 to 4.38)
Concurrent prednisolone use 1.07 (0.56 to 2.06) 1.09 (0.53 to 2.22) 1.08 (0.50 to 2.33)
DAS28 (per unit increase) 1.13 (0.91 to 1.40) 1.06 (0.84 to 1.34) 1.10 (0.86 to 1.41)
Swollen joint count (<10, 10–17, >17) 0.96 (0.66 to 1.41) 0.94 (0.62 to 1.43) 1.06 (0.68 to 1.64)
Tender joint count (per 10 increase) 0.83 (0.57 to 1.22) 0.75 (0.50 to 1.14) 0.81 (0.52 to 1.26)
CRP (<10, 10–35 vs >35 mg/dL) 1.43 (1.07 to 1.92) 1.42 (1.04 to 1.94) 1.30 (0.92 to 1.82)
ESR (<21, 21–50, >50 mm/h) 1.65 (1.29 to 2.28) 1.64 (1.15 to 2.33) 1.63 (1.12 to 2.37)
VAS–global health (per 10 increase) 1.03 (0.94 to 1.14) 1.01 (0.91 to 1.11) 1.00 (0.90 to 1.11)
HAQ (per unit increase) 1.12 (0.79 to 1.60) 1.00 (0.68 to 1.45) 0.93 (0.62 to 1.40)
HLA-DRB1 shared epitope positive 1.47 (0.85 to 2.53) 1.32 (0.74 to 2.36) 1.07 (0.58 to 1.98)
*Association between each parameter and the odds of having a rapid radiographic progression after 1 year (yes/no), calculated by logistic regression and expressed as ORs with 95%
CIs. ORs for dichotomised variables are calculated for being positive, and for continuous variables per unit (DAS28, HAQ) or per 10 increase (age, VAS–global health), while CRP and
ESR was grouped as in previous reports which corresponded to tertiles, and symptom duration per month increase.
†Adjusted for gender symptom duration, current smoking, baseline erosions and HAQ.
‡As high co-linearity was observed for anti-CCP and RF status, and also HAQ score and DAS28 and its components, only anti-CCP status and HAQ were kept in the model, and
excluded when RF status or DAS28 and its components, respectively, were analysed.
§Three group comparison, double positive (2), single positive (1), no positive (0).
Abbreviations and numbers of missing as in table 1.
Anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SHS, Sharp–van
der Heijde.
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CRP and baseline erosions that progressed was lower (0%) than
in the group with no baseline erosions (17%). The treatment in
these two subgroups did not differ (even numbers randomised
to either treatment) and we have no clear explanation but
would like to interpret this ﬁnding with caution, since the
proportion with progression in both subgroups was relatively
low (0% and 17%) and only one other subgroup had risk
below 20%.
One potential limitation is that data on smoking intensity
(pack-years) was not available. However, a previous study did
not ﬁnd any association with outcome when pack-years were
evaluated in the context of the actual smoking status (current,
past, never smoker),14 indicating that the actual smoking habits
have most impact. Furthermore, our study was not designed to
elucidate the mechanisms through which smoking affects radio-
graphic progression. There is limited evidence available on this
and mechanistic studies are required. Our study conﬁrmed the
broad evidence that there is a higher proportion of RF/anti-CCP
positivity in current than in non-current smokers (double posi-
tive 61% vs 46%, single positive 29% vs 29%, double negative
10% vs 25%, p=0.01).
Taken together, our ﬁndings conﬁrm and extend previous
reports on predictors for radiographic progression in early RA
and highlight the risk associated with smoking. The identiﬁed
predictors are easily accessible and objective clinical variables,
and showed clinically meaningful differences when tested in risk
matrixes. Being based on a trial that reﬂects standard care in
Sweden, the external validity of this risk matrix should be high,
and now awaits validation in other early RA populations with
available data on smoking status.
Figure 2 Risk matrices showing the proportion of SWEFOT patients
who have developed radiographic progression (% and number with
increase in Sharp–van der Hejde score ≥5 divided by total number in
group) after 1 year in all early rheumatoid arthritis patients and
stratiﬁed by treatment month 3–12. CRP, C-reactive protein; RRP, rapid
radiographic progression.
Figure 3 Risk matrices showing the proportion of SWEFOT patients
who have developed radiographic progression (% and number with
increase in Sharp–van der Hejde score ≥5 divided by total number in
group) after 1 year in all early rheumatoid arthritis patients and
stratiﬁed by sex. CRP, C-reactive protein; RRP, rapid radiographic
progression.
Figure 1 Risk matrices showing the proportion of SWEFOT patients
who have developed radiographic progression (% and number with
increase in Sharp–van der Hejde score ≥5 divided by total number in
group) after 1 year, sub-grouped by baseline parameters identiﬁed
using multivariable logistic regression analysis in the whole group and
stratiﬁed by anti-cyclic citrullinated peptide (anti-CCP) status. Finally,
we tested a previously reported matrix by Visser et al.5 CRP, C-reactive
protein; RF, rheumatoid factor; RRP, rapid radiographic progression.
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